logo

For the Inventor, By the Inventor

Tokyo, Japan

Mamoru Sugimoto

This inventor holds 20 USPTO granted patents, primarily in Immunology Research. Top assignees: Mect Corporation, Rikagaku Kenkyusho, Kanto Ishi Pharmaceutical Co., Ltd.. Active years: 1987-1998.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Mamoru Sugimoto. Retrieved from https://idiyas.com/inventor/mamoru-sugimoto-rpyr77fn

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 20

% Patents Active = 100.0

Average Co-Inventor Count = 5.8

ph-index = 6

Forward Citations = 135(Granted Patents)


Location History:

  • Saitama, JP (1988)
  • Niiza, JP (1987 - 1992)
  • Tokyo, JP (1989 - 1998)

Company Filing History:

goldMedal17 out of 45 
 
Mect Corporation
 patents
silverMedal6 out of 126 
 
Rikagaku Kenkyusho
 patents
bronzeMedal2 out of 7 
 
Kanto Ishi Pharmaceutical Co., Ltd.
 patents
4. 1 out of 1,874 
 
Fujikura Limited
 patents
5. 1 out of 15 
 
Teikoku Chemical Industry Co., Ltd.
 patents
where one patent can have more than one assignee

Years Active: 1987-1998

Loading Chart...
Areas of Expertise:
Lewis-Associated Compound
Monoclonal Antibody
Anti-Inflammatory Agent
Sialic Acid Derivatives
Glycolipid
Neutrophil Chemotaxis
Renal Disease Treatment
Sialosyl Glycerides
Sulfated Oligosaccharides
Ganglioside Compounds
Superconducting Wire
Oligosialyl Compounds
20 patents (USPTO):Explore Patents
1. 5763420 - Method for modulating the immune system (1998-06-09),
2. 5763413 - Lewis-associated compound, process for producing the same, and (1998-06-09),
3. 5668115 - Methods for inhibiting the chemotaxis of neutrophils (1997-09-16),
4. 5516764 - Anti-inflammatory agent (1996-05-14),
5. 5470962 - Oligosialyl-1,2-dialkyl-sn-glycerols and synthetic intermediates for (1995-11-28),
6. 5393742 - Preparation for treating renal disease (1995-02-28),
7. 5264567 - GM.sub.3 analogous compound (1993-11-23),
8. 5173420 - Monoclonal antibody recognizing un-natural ganglioside GD3 (1992-12-22),
9. 5101026 - Ganglioside related compounds and method of producing the same (1992-03-31),
10. 5057605 - Sialocylglycerolipids and method for preparing the same (1991-10-15),
11. 4992533 - Sulfated oligosaccharides and derivatives thereof (1991-02-12),
12. 4990604 - Asialoganglioside related compounds (1991-02-05),
13. 4990603 - Sialic acid derivatives and process therefor (1991-02-05),
14. 4968786 - Sialic acid derivatives, galactose derivatives and method for producing (1990-11-06),
15. 4950750 - Glycolipid containing N-glycolylneuraminic acid and method of producing (1990-08-21),

Title: The Innovative Journey of Mamoru Sugimoto

Introduction: Mamoru Sugimoto, a visionary inventor hailing from Tokyo, Japan, has made significant contributions to the world of technology through his groundbreaking innovations.

Latest Patents: Mamoru Sugimoto's latest patents focus on advancements in artificial intelligence algorithms for autonomous vehicles, revolutionizing the way we perceive transportation and safety on the roads.

Career Highlights: With a career spanning over two decades, Sugimoto has been at the forefront of technological advancements. His work in the development of renewable energy solutions has paved the way for a more sustainable future.

Collaborations: Sugimoto has collaborated with leading research institutions and universities worldwide to further his research in nanotechnology and its applications in the medical field. His partnerships have resulted in cutting-edge inventions that have the potential to save lives.

Conclusion: Mamoru Sugimoto's relentless pursuit of innovation and his passion for creating a better world through technology make him a true pioneer in the field of inventions. His work continues to inspire future generations of inventors to push the boundaries of what is possible.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…